Drug Approval | June 25, 2024
Lupin receives EIR from US FDA for its Somerset manufacturing facility
The facility was inspected from May 7 to May 17, 2024
The facility was inspected from May 7 to May 17, 2024
PEKK is a high-performance polymer family used in aerospace and other demanding markets
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH
Innovative technologies and comprehensive services to strengthen Syntegon’s strategic growth
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas
Scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer and GSK will continue to vigorously defend itself against all claims
Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
Subscribe To Our Newsletter & Stay Updated
